Concepts (114)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Failure, Acute | 1 | 2020 | 99 | 0.630 |
Why?
|
| Echocardiography | 3 | 2020 | 1228 | 0.620 |
Why?
|
| Shock, Cardiogenic | 1 | 2020 | 193 | 0.600 |
Why?
|
| Dyspnea | 2 | 2013 | 420 | 0.430 |
Why?
|
| Pulmonary Edema | 1 | 2013 | 81 | 0.420 |
Why?
|
| Clinical Competence | 2 | 2019 | 1325 | 0.400 |
Why?
|
| Endocarditis | 1 | 2013 | 126 | 0.390 |
Why?
|
| Hypotension | 1 | 2013 | 232 | 0.380 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2013 | 170 | 0.380 |
Why?
|
| Critical Care | 3 | 2019 | 796 | 0.350 |
Why?
|
| Antimalarials | 1 | 2009 | 55 | 0.340 |
Why?
|
| Malaria, Falciparum | 1 | 2009 | 48 | 0.340 |
Why?
|
| Sjogren's Syndrome | 1 | 2009 | 105 | 0.300 |
Why?
|
| Lung Diseases | 2 | 2013 | 755 | 0.290 |
Why?
|
| Heart Failure | 1 | 2020 | 2330 | 0.270 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2009 | 331 | 0.260 |
Why?
|
| Sexual and Gender Minorities | 1 | 2022 | 77 | 0.190 |
Why?
|
| Cardiac Output | 2 | 2020 | 194 | 0.190 |
Why?
|
| Ultrasonography | 3 | 2020 | 1933 | 0.190 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2021 | 161 | 0.180 |
Why?
|
| Jaundice | 1 | 2020 | 39 | 0.170 |
Why?
|
| Pulmonary Embolism | 2 | 2013 | 342 | 0.170 |
Why?
|
| Diuretics | 1 | 2020 | 170 | 0.160 |
Why?
|
| Cardiotonic Agents | 1 | 2020 | 156 | 0.160 |
Why?
|
| Tracheal Neoplasms | 1 | 2018 | 44 | 0.150 |
Why?
|
| Respiratory Insufficiency | 1 | 2021 | 344 | 0.150 |
Why?
|
| Stroke Volume | 1 | 2020 | 544 | 0.150 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2019 | 289 | 0.140 |
Why?
|
| Point-of-Care Systems | 1 | 2020 | 212 | 0.140 |
Why?
|
| Pulmonary Atelectasis | 1 | 2017 | 51 | 0.140 |
Why?
|
| Oncogene Proteins | 1 | 2018 | 367 | 0.140 |
Why?
|
| Bronchiolitis Obliterans | 1 | 2017 | 94 | 0.130 |
Why?
|
| Thrombosis | 1 | 2021 | 743 | 0.120 |
Why?
|
| Hypertension, Pulmonary | 2 | 2010 | 464 | 0.120 |
Why?
|
| HIV Infections | 2 | 2022 | 2154 | 0.120 |
Why?
|
| Radiography, Thoracic | 2 | 2013 | 477 | 0.110 |
Why?
|
| Critical Illness | 1 | 2019 | 739 | 0.110 |
Why?
|
| Silicosis | 1 | 2013 | 6 | 0.110 |
Why?
|
| Occupational Diseases | 1 | 2013 | 131 | 0.100 |
Why?
|
| Atrial Fibrillation | 1 | 2020 | 730 | 0.100 |
Why?
|
| Pandemics | 1 | 2021 | 1610 | 0.100 |
Why?
|
| Angiography | 1 | 2013 | 350 | 0.100 |
Why?
|
| Mitral Valve | 1 | 2013 | 269 | 0.090 |
Why?
|
| Heart Valve Prosthesis | 1 | 2013 | 306 | 0.080 |
Why?
|
| Humans | 14 | 2022 | 270740 | 0.070 |
Why?
|
| Internship and Residency | 1 | 2019 | 1452 | 0.070 |
Why?
|
| Nuclear Proteins | 1 | 2018 | 3438 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2013 | 7783 | 0.070 |
Why?
|
| Carcinoma | 1 | 2018 | 2610 | 0.070 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2009 | 216 | 0.070 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2009 | 878 | 0.070 |
Why?
|
| Hemodynamics | 1 | 2010 | 949 | 0.070 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2009 | 381 | 0.070 |
Why?
|
| Antirheumatic Agents | 1 | 2009 | 230 | 0.070 |
Why?
|
| Male | 8 | 2022 | 128315 | 0.060 |
Why?
|
| Middle Aged | 5 | 2021 | 90352 | 0.060 |
Why?
|
| Rituximab | 1 | 2009 | 1594 | 0.060 |
Why?
|
| Severity of Illness Index | 2 | 2010 | 4372 | 0.050 |
Why?
|
| Homosexuality, Male | 1 | 2022 | 75 | 0.050 |
Why?
|
| Acute Kidney Injury | 1 | 2009 | 761 | 0.050 |
Why?
|
| Partial Thromboplastin Time | 1 | 2021 | 51 | 0.050 |
Why?
|
| Minority Groups | 1 | 2022 | 328 | 0.040 |
Why?
|
| Fibrinolytic Agents | 1 | 2021 | 293 | 0.040 |
Why?
|
| Population Surveillance | 1 | 2022 | 647 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2021 | 33737 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2009 | 4481 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2018 | 12033 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2017 | 822 | 0.030 |
Why?
|
| Prognosis | 2 | 2009 | 22505 | 0.030 |
Why?
|
| Adult | 5 | 2022 | 82040 | 0.030 |
Why?
|
| Dentists | 1 | 2013 | 11 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2019 | 1570 | 0.030 |
Why?
|
| Predictive Value of Tests | 2 | 2013 | 4960 | 0.030 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2013 | 66 | 0.030 |
Why?
|
| Unnecessary Procedures | 1 | 2013 | 101 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 4492 | 0.020 |
Why?
|
| Adolescent | 2 | 2022 | 32767 | 0.020 |
Why?
|
| Young Adult | 2 | 2021 | 22251 | 0.020 |
Why?
|
| Technetium Tc 99m Pentetate | 1 | 2010 | 13 | 0.020 |
Why?
|
| Aged | 4 | 2021 | 73333 | 0.020 |
Why?
|
| Vascular Resistance | 1 | 2010 | 213 | 0.020 |
Why?
|
| Endothelin Receptor Antagonists | 1 | 2009 | 26 | 0.020 |
Why?
|
| Dobutamine | 1 | 2009 | 59 | 0.020 |
Why?
|
| Prostaglandins | 1 | 2009 | 83 | 0.020 |
Why?
|
| Milrinone | 1 | 2009 | 31 | 0.020 |
Why?
|
| Female | 5 | 2022 | 148940 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2013 | 681 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 2010 | 655 | 0.020 |
Why?
|
| Respiratory Function Tests | 1 | 2010 | 354 | 0.020 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2009 | 71 | 0.020 |
Why?
|
| Causality | 1 | 2009 | 176 | 0.020 |
Why?
|
| Retrospective Studies | 3 | 2021 | 39890 | 0.020 |
Why?
|
| Vasoconstrictor Agents | 1 | 2009 | 166 | 0.020 |
Why?
|
| Aged, 80 and over | 3 | 2013 | 30998 | 0.020 |
Why?
|
| Acute Disease | 1 | 2013 | 2493 | 0.020 |
Why?
|
| Anti-Retroviral Agents | 1 | 2009 | 146 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2013 | 1824 | 0.020 |
Why?
|
| ROC Curve | 1 | 2010 | 1248 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2018 | 3345 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2021 | 15218 | 0.020 |
Why?
|
| Respiration, Artificial | 1 | 2009 | 585 | 0.020 |
Why?
|
| United States | 1 | 2022 | 15861 | 0.020 |
Why?
|
| Lung Transplantation | 1 | 2009 | 383 | 0.020 |
Why?
|
| Radiopharmaceuticals | 1 | 2010 | 1341 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2010 | 1568 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2013 | 4831 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2009 | 2345 | 0.010 |
Why?
|
| Comorbidity | 1 | 2009 | 2394 | 0.010 |
Why?
|
| Prevalence | 1 | 2009 | 3404 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2010 | 6177 | 0.010 |
Why?
|
| Biomarkers, Tumor | 1 | 2018 | 10708 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2010 | 9470 | 0.010 |
Why?
|
| Survival Rate | 1 | 2009 | 12541 | 0.010 |
Why?
|
| Risk Factors | 1 | 2013 | 17888 | 0.010 |
Why?
|